UK markets closed

Regencell Bioscience Holdings Limited (RGC)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
5.35-0.30 (-5.31%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 69.62M
Enterprise value 58.52M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)5.79
Enterprise value/revenue N/A
Enterprise value/EBITDA -10.63

Trading information

Stock price history

Beta (5Y monthly) -0.35
52-week change 3-80.03%
S&P500 52-week change 321.08%
52-week high 330.49
52-week low 33.16
50-day moving average 35.17
200-day moving average 311.41

Share statistics

Avg vol (3-month) 34.22k
Avg vol (10-day) 35.96k
Shares outstanding 513.01M
Implied shares outstanding 613.01M
Float 81.46M
% held by insiders 188.76%
% held by institutions 10.12%
Shares short (15 Apr 2024) 49.88k
Short ratio (15 Apr 2024) 41.57
Short % of float (15 Apr 2024) 40.40%
Short % of shares outstanding (15 Apr 2024) 40.08%
Shares short (prior month 15 Mar 2024) 45.1k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Jun 2023
Most-recent quarter (mrq)30 Jun 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-25.59%
Return on equity (ttm)-41.71%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -5.98M
Net income avi to common (ttm)-5.87M
Diluted EPS (ttm)-0.45
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)11.56M
Total cash per share (mrq)0.89
Total debt (mrq)463.67k
Total debt/equity (mrq)3.87%
Current ratio (mrq)19.15
Book value per share (mrq)0.92

Cash flow statement

Operating cash flow (ttm)-4.96M
Levered free cash flow (ttm)-2.28M